Compare Procter & Gamble Co (PG) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Twist Bioscience Corp — how do they compare? Procter & Gamble Co trades at $149.49 (market cap $344.87B), while Twist Bioscience Corp trades at $93.82 (market cap $5.97B). The key difference: Procter & Gamble Co is far larger — about 57.8× Twist Bioscience Corp's market cap, and Procter & Gamble Co pays a 2.94% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| PG | TWST | |
|---|---|---|
Market Cap | $344.87B | $5.97B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $102.88 |
52-Week Low | $138.10 | $24.16 |
Enterprise Value | $370.34B | $5.89B |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement with a neutral technical stance. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.59 versus $1.56 expected, and robust profitability metrics like a 50.33% gross margin. Recent developments include a multi-year WNBA partnership and ongoing dividend payments of $1.09 per share, supporting its defensive appeal amid market volatility.
PG offers stability with a 53.85% analyst buy rating and $160.50 consensus target, but premium valuations (P/E 21.65) and modest growth outlook pose near-term risks. Supply chain efficiencies and brand strength underpin resilience, though inflation and competitive pressures require monitoring for sustained shareholder returns.
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
